Skip to content

EBIT at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$10.8M-131%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$19.46M-6.8%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Calculated from Nuvectis Pharma, Inc.’s reported figures.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s EBIT?
Nuvectis Pharma, Inc. (NVCT) reported EBIT of -$6.26M in Q1 2026.
How has Nuvectis Pharma, Inc.'s EBIT changed year-over-year?
Nuvectis Pharma, Inc.'s EBIT decreased by 12.4% year-over-year, from -$5.57M to -$6.26M.
What is the long-term trend for Nuvectis Pharma, Inc.'s EBIT?
Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s EBIT has grown at a 20.9% compound annual growth rate (CAGR), from -$12.89M to -$27.57M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.